ConvaTec Group Plc CTEC
LSE · United Kingdom · Health Technology
GBp 215.80-1.20 (-0.55%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
BOSTON & LONDON, September 28, 2026--Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, announces the launch of Cure Aqua™ in the United States and Canada.
The global ostomy dressings market is projected to grow from USD 3.80 billion in 2026 to USD 4.73 billion by 2031, at a 4.4% CAGR. Growth is driven by rising colorectal cancer and inflammatory bowel disease cases, aging populations, improved peristomal skin care awareness, and expanding home care services. Skin barrier rings will record the fastest product growth, while Asia Pacific will be the fastest-growing region. Key companies include Coloplast, ConvaTec, Hollister, B. Braun, Solventum, and
ConvaTec Group (LON:CTEC) said it remained on track to meet its 2026 financial targets after reporting 5% organic revenue growth in the first half, excluding the impact of its InnovaMatrix skin-substitute product. The company said revenue growth was broad-based across its four chronic-care categori
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.